Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has executed a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l. and submitted a revised application under the European Funds for the Modern Economy SMART Path program. The updated application seeks €12 million in non-dilutive, non-repayable funding to support a €15 million integrated R&D program for PC111, a fully human monoclonal antibody targeting soluble Fas Ligand for the treatment of pemphigus vulgaris and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis. This represents 80% co-financing for the development program.
The amendment extends the option condition deadline to Aug. 31, 2026, and the exercise period to Sept. 30, 2026, aligning with the anticipated three- to four-month grant review timeline as the company advances PC111 toward early clinical development and human proof of concept. This strategic timing allows Scinai to potentially secure substantial non-dilutive funding before committing to the full acquisition of PinCell, which could significantly reduce financial risk for the company and its shareholders.
The importance of this development lies in the potential advancement of PC111, which targets two serious and often life-threatening autoimmune conditions. Pemphigus vulgaris is a rare autoimmune blistering disease that affects the skin and mucous membranes, while Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis are severe skin reactions typically triggered by medications. Both conditions have limited treatment options and can result in significant morbidity and mortality. The development of targeted monoclonal antibody therapies represents a promising approach for these underserved patient populations.
For the biotechnology industry, Scinai's approach demonstrates strategic financial planning by seeking non-dilutive European grant funding before exercising acquisition options. The SMART Path program, part of the European Funds for the Modern Economy, provides significant support for innovative research projects. If approved, the €12 million grant would cover 80% of the €15 million integrated R&D program, substantially reducing the financial burden on Scinai while advancing a potentially important therapeutic candidate.
The company's latest news and updates relating to SCNI are available in the company's newsroom at https://ibn.fm/SCNI. For more information about MissionIR, which distributed the press release, please visit https://www.MissionIR.com. The full terms of use and disclaimers applicable to all content provided by MIR are available at https://www.MissionIR.com/Disclaimer.
This development matters because it represents a coordinated financial and strategic approach to advancing rare disease therapeutics. By aligning grant application timelines with acquisition option extensions, Scinai demonstrates prudent risk management while pursuing innovative treatments for conditions with significant unmet medical needs. The potential €12 million in non-repayable funding could accelerate development timelines and reduce shareholder dilution, while the targeted acquisition of PinCell would strengthen Scinai's immunology pipeline. For patients suffering from these rare autoimmune conditions, progress toward clinical development of PC111 offers hope for more effective, targeted treatments that address the underlying mechanisms of their diseases.
